Global Uterine Cancer Therapies and Diagnostic Market Research Report 2023

Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus.

The global Uterine Cancer Therapies and Diagnostic market was valued at US$ 21650 million in 2022 and is anticipated to reach US$ 28120 million by 2029, witnessing a CAGR of 4.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Uterine Cancer Therapies and Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Uterine Cancer Therapies and Diagnostic is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Uterine Cancer Therapies and Diagnostic in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Uterine Cancer Therapies and Diagnostic include Ariad Pharmaceuticals, Merck, AbbVie and BD, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Uterine Cancer Therapies and Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Uterine Cancer Therapies and Diagnostic.

The Uterine Cancer Therapies and Diagnostic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Uterine Cancer Therapies and Diagnostic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Uterine Cancer Therapies and Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Uterine Sarcomas

1.2.3 Endometrial Carcinomas

1.3 Market by Application

1.3.1 Global Uterine Cancer Therapies and Diagnostic Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Centers

1.3.4 Specialty Clinics

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Uterine Cancer Therapies and Diagnostic Market Perspective (2018-2029)

2.2 Uterine Cancer Therapies and Diagnostic Growth Trends by Region

2.2.1 Global Uterine Cancer Therapies and Diagnostic Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Uterine Cancer Therapies and Diagnostic Historic Market Size by Region (2018-2023)

2.2.3 Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Region (2024-2029)

2.3 Uterine Cancer Therapies and Diagnostic Market Dynamics

2.3.1 Uterine Cancer Therapies and Diagnostic Industry Trends

2.3.2 Uterine Cancer Therapies and Diagnostic Market Drivers

2.3.3 Uterine Cancer Therapies and Diagnostic Market Challenges

2.3.4 Uterine Cancer Therapies and Diagnostic Market Restraints

3.1 Global Top Uterine Cancer Therapies and Diagnostic Players by Revenue

3.1.1 Global Top Uterine Cancer Therapies and Diagnostic Players by Revenue (2018-2023)

3.1.2 Global Uterine Cancer Therapies and Diagnostic Revenue Market Share by Players (2018-2023)

3.2 Global Uterine Cancer Therapies and Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Uterine Cancer Therapies and Diagnostic Revenue

3.4 Global Uterine Cancer Therapies and Diagnostic Market Concentration Ratio

3.4.1 Global Uterine Cancer Therapies and Diagnostic Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Uterine Cancer Therapies and Diagnostic Revenue in 2022

3.5 Uterine Cancer Therapies and Diagnostic Key Players Head office and Area Served

3.6 Key Players Uterine Cancer Therapies and Diagnostic Product Solution and Service

3.7 Date of Enter into Uterine Cancer Therapies and Diagnostic Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Uterine Cancer Therapies and Diagnostic Historic Market Size by Type (2018-2023)

4.2 Global Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Type (2024-2029)

5.1 Global Uterine Cancer Therapies and Diagnostic Historic Market Size by Application (2018-2023)

5.2 Global Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Application (2024-2029)

6.1 North America Uterine Cancer Therapies and Diagnostic Market Size (2018-2029)

6.2 North America Uterine Cancer Therapies and Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023)

6.4 North America Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Uterine Cancer Therapies and Diagnostic Market Size (2018-2029)

7.2 Europe Uterine Cancer Therapies and Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023)

7.4 Europe Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size (2018-2029)

8.2 Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size by Region (2018-2023)

8.4 Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Uterine Cancer Therapies and Diagnostic Market Size (2018-2029)

9.2 Latin America Uterine Cancer Therapies and Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023)

9.4 Latin America Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size (2018-2029)

10.2 Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023)

10.4 Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Ariad Pharmaceuticals

11.1.1 Ariad Pharmaceuticals Company Detail

11.1.2 Ariad Pharmaceuticals Business Overview

11.1.3 Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Introduction

11.1.4 Ariad Pharmaceuticals Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

11.1.5 Ariad Pharmaceuticals Recent Development

11.2 Merck

11.2.1 Merck Company Detail

11.2.2 Merck Business Overview

11.2.3 Merck Uterine Cancer Therapies and Diagnostic Introduction

11.2.4 Merck Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

11.2.5 Merck Recent Development

11.3 AbbVie

11.3.1 AbbVie Company Detail

11.3.2 AbbVie Business Overview

11.3.3 AbbVie Uterine Cancer Therapies and Diagnostic Introduction

11.3.4 AbbVie Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

11.3.5 AbbVie Recent Development

11.4 BD

11.4.1 BD Company Detail

11.4.2 BD Business Overview

11.4.3 BD Uterine Cancer Therapies and Diagnostic Introduction

11.4.4 BD Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

11.4.5 BD Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Uterine Sarcomas

    Table 3. Key Players of Endometrial Carcinomas

    Table 4. Global Uterine Cancer Therapies and Diagnostic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Uterine Cancer Therapies and Diagnostic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Uterine Cancer Therapies and Diagnostic Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Uterine Cancer Therapies and Diagnostic Market Share by Region (2018-2023)

    Table 8. Global Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Uterine Cancer Therapies and Diagnostic Market Share by Region (2024-2029)

    Table 10. Uterine Cancer Therapies and Diagnostic Market Trends

    Table 11. Uterine Cancer Therapies and Diagnostic Market Drivers

    Table 12. Uterine Cancer Therapies and Diagnostic Market Challenges

    Table 13. Uterine Cancer Therapies and Diagnostic Market Restraints

    Table 14. Global Uterine Cancer Therapies and Diagnostic Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Uterine Cancer Therapies and Diagnostic Market Share by Players (2018-2023)

    Table 16. Global Top Uterine Cancer Therapies and Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Uterine Cancer Therapies and Diagnostic as of 2022)

    Table 17. Ranking of Global Top Uterine Cancer Therapies and Diagnostic Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Uterine Cancer Therapies and Diagnostic Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Uterine Cancer Therapies and Diagnostic Product Solution and Service

    Table 21. Date of Enter into Uterine Cancer Therapies and Diagnostic Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Uterine Cancer Therapies and Diagnostic Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Uterine Cancer Therapies and Diagnostic Revenue Market Share by Type (2018-2023)

    Table 25. Global Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Uterine Cancer Therapies and Diagnostic Revenue Market Share by Type (2024-2029)

    Table 27. Global Uterine Cancer Therapies and Diagnostic Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Uterine Cancer Therapies and Diagnostic Revenue Market Share by Application (2018-2023)

    Table 29. Global Uterine Cancer Therapies and Diagnostic Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Uterine Cancer Therapies and Diagnostic Revenue Market Share by Application (2024-2029)

    Table 31. North America Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Ariad Pharmaceuticals Company Detail

    Table 47. Ariad Pharmaceuticals Business Overview

    Table 48. Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Product

    Table 49. Ariad Pharmaceuticals Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023) & (US$ Million)

    Table 50. Ariad Pharmaceuticals Recent Development

    Table 51. Merck Company Detail

    Table 52. Merck Business Overview

    Table 53. Merck Uterine Cancer Therapies and Diagnostic Product

    Table 54. Merck Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023) & (US$ Million)

    Table 55. Merck Recent Development

    Table 56. AbbVie Company Detail

    Table 57. AbbVie Business Overview

    Table 58. AbbVie Uterine Cancer Therapies and Diagnostic Product

    Table 59. AbbVie Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023) & (US$ Million)

    Table 60. AbbVie Recent Development

    Table 61. BD Company Detail

    Table 62. BD Business Overview

    Table 63. BD Uterine Cancer Therapies and Diagnostic Product

    Table 64. BD Revenue in Uterine Cancer Therapies and Diagnostic Business (2018-2023) & (US$ Million)

    Table 65. BD Recent Development

    Table 66. Research Programs/Design for This Report

    Table 67. Key Data Information from Secondary Sources

    Table 68. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Uterine Cancer Therapies and Diagnostic Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Uterine Cancer Therapies and Diagnostic Market Share by Type: 2022 VS 2029

    Figure 3. Uterine Sarcomas Features

    Figure 4. Endometrial Carcinomas Features

    Figure 5. Global Uterine Cancer Therapies and Diagnostic Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Uterine Cancer Therapies and Diagnostic Market Share by Application: 2022 VS 2029

    Figure 7. Hospitals Case Studies

    Figure 8. Ambulatory Surgical Centers Case Studies

    Figure 9. Specialty Clinics Case Studies

    Figure 10. Others Case Studies

    Figure 11. Uterine Cancer Therapies and Diagnostic Report Years Considered

    Figure 12. Global Uterine Cancer Therapies and Diagnostic Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Uterine Cancer Therapies and Diagnostic Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Uterine Cancer Therapies and Diagnostic Market Share by Region: 2022 VS 2029

    Figure 15. Global Uterine Cancer Therapies and Diagnostic Market Share by Players in 2022

    Figure 16. Global Top Uterine Cancer Therapies and Diagnostic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Uterine Cancer Therapies and Diagnostic as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Uterine Cancer Therapies and Diagnostic Revenue in 2022

    Figure 18. North America Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Uterine Cancer Therapies and Diagnostic Market Share by Country (2018-2029)

    Figure 20. United States Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Uterine Cancer Therapies and Diagnostic Market Share by Country (2018-2029)

    Figure 24. Germany Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Uterine Cancer Therapies and Diagnostic Market Share by Region (2018-2029)

    Figure 32. China Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Uterine Cancer Therapies and Diagnostic Market Share by Country (2018-2029)

    Figure 40. Mexico Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Uterine Cancer Therapies and Diagnostic Market Share by Country (2018-2029)

    Figure 44. Turkey Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Uterine Cancer Therapies and Diagnostic Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Ariad Pharmaceuticals Revenue Growth Rate in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

    Figure 47. Merck Revenue Growth Rate in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

    Figure 48. AbbVie Revenue Growth Rate in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

    Figure 49. BD Revenue Growth Rate in Uterine Cancer Therapies and Diagnostic Business (2018-2023)

    Figure 50. Bottom-up and Top-down Approaches for This Report

    Figure 51. Data Triangulation

    Figure 52. Key Executives Interviewed